Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections – Pipeline Review, H2 2017’, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections

The report reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections therapeutics and enlists all their major and minor projects

The report assesses Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CrystalGenomics Inc

Debiopharm International SA

Destiny Pharma Ltd

iNtRON Biotechnology Inc

TSRL Inc

Wockhardt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Overview

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Companies Involved in Therapeutics Development

CrystalGenomics Inc

Debiopharm International SA

Destiny Pharma Ltd

iNtRON Biotechnology Inc

TSRL Inc

Wockhardt Ltd

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Drug Profiles

afabicin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-400549 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epidermicin NI-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exeporfinium chloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PBP2 for Gram-Positive Bacterial Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PBP2a for Gram-Positive Bacterial Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Bacterial Cell Wall for MRSA and VRSA Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for MRSA and VRSA Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Methionine tRNA Ligase for Gram Positive Bacterial Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target Bacterial Cell Wall for Vancomycin-Resistant Enterococcus faecium and Staphylococcus aureus Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tonabacase Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WCK-4086 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Dormant Projects

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline by CrystalGenomics Inc, H2 2017

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline by Debiopharm International SA, H2 2017

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline by Destiny Pharma Ltd, H2 2017

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline by iNtRON Biotechnology Inc, H2 2017

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline by TSRL Inc, H2 2017

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline by Wockhardt Ltd, H2 2017

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Dormant Projects, H2 2017

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports